14-day Premium Trial Subscription Try For FreeTry Free
Currently predicting for Wed, 24 Apr 2024

Trading levels for MBRX

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 4.94 14.88 %
R2 4.76 10.62 %
R1 4.64 7.99 %
Current price: 4.30
Support S1 4.28 -0.543 %
S2 4.16 -3.18 %
S3 3.98 -7.44 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 5.25 22.09 %
R2 5.20 20.93 %
R1 4.68 8.84 %
Current price 4.30
Support S1 4.28 -0.465%
S2 0 .
S3 0 .

MBRX Predictions History

2 years ago
AlexVel predicted that MBRX for 2021-11-26 is going $2.23 (3.72%)

2 years ago
Rybkarybka predicted that MBRX for 2021-11-26 is going $2.38 (8.18%)

3 years ago
JS predicted that MBRX for 2021-02-09 is going $4.93 (-3.71%)

3 years ago
MajedAlshaikhhussain predicted that MBRX for 2021-02-09 is going

Rank:

3 years ago
JS predicted that MBRX for 2021-01-14 is going $0.99 (-2.38%)

3 years ago
JS predicted that MBRX for 2020-11-18 is going $0.797 (3.49%)

4 years ago
JS predicted that MBRX for 2020-04-16 is going $1.21 (-17.69%)

4 years ago
NameNotImportant predicted that MBRX for 2019-05-02 is going $1.04 (-17.46%)

4 years ago
Osama.Abd.108788 predicted that MBRX for 2019-04-29 is going $2.97 (109.15%)

Rank:

4 years ago
JS predicted that MBRX for 2019-04-26 is going $1.58 (11.27%)

Click to get the best stock tips daily for free!

About Moleculin Biotech Inc

Moleculin Biotech Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial fo... MBRX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT